Gathering the record
Relay is organizing the evidence and source boundaries.
Heterogeneous animal-derived peptide mixture
An animal-brain-derived peptide mixture researched for neurological conditions. It is not one defined peptide.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Randomized clinical reports exist, including stroke and chronic cerebral ischemia studies, but much of the literature is regionally concentrated and does not establish broad regulatory consensus.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Trials report adverse events within their study windows, but heterogeneous sourcing and limited independent surveillance constrain uncommon-event assessment.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceTrials report adverse events within their study windows, but heterogeneous sourcing and limited independent surveillance constrain uncommon-event assessment.
Controlled human evidenceLow-frequency estimates are sensitive to sample size, follow-up, ascertainment, formulation, and population.
Open sourceRelay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryMarketed in some countries; not FDA-approved in the United States. Which components are active, whether results independently replicate across standardized formulations, and how benefit-risk compares with established care.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
IV · Into a vein
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
A 490-patient regional trial compared defined IV and IM Cortexin formulations after ischemic stroke.
| Stage / period | Amount | Frequency |
|---|---|---|
| First course · 10 days | 10 mg IV | Twice daily |
The active comparison was between routes, not Cortexin versus no active treatment. The source's product-specific regimen is not a general cognition protocol or a dose for another peptide mixture. Both groups later received a second IM course; the IV view shows the first course only.
Cortexin · therapeutic-equivalence stroke trial Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A multicenter randomized, blinded study investigated two administration forms of Cortexin in adults with acute ischemic stroke and followed outcomes for ninety days.
Population: Adults with acute ischemic stroke
Design: Multicenter randomized double-blind active-form comparison
Mechanisms
Published clinical reports have studied branded Cortexin formulations in neurologic settings. Results apply to the tested mixture and design, not to an inferred active sequence or every product sold under the name.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
No single validated target is established in the current record.
Research reference
A reference for the studies, populations, and routes behind this profile.
Limited and regionally concentrated human evidence; mixture identity and independent replication remain important constraints.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Which components are active, whether results independently replicate across standardized formulations, and how benefit-risk compares with established care.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Both groups received Cortexin, so the study does not establish benefit versus placebo or standard care. The animal-derived mixture, regional setting, and lack of independent formulation-standardized replication limit transferability. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Multicenter randomized double-blind active-form comparison
Adults with acute ischemic stroke
A 490-participant randomized double-blind study compared two administration forms over a 90-day follow-up.
Study administration: Cortexin intravenous versus intramuscular form
Limitations: Both groups received Cortexin; this does not establish benefit versus standard care or placebo.
Randomized comparative clinical study
Adults with chronic cerebral ischemia
Endpoints were not fully described in the current record.
A randomized dose-comparison report evaluated 10 mg and 20 mg regimens against a comparison group.
Study administration: Not stated in the current record.
Limitations: Regional publication, formulation-specific findings, and limited independent replication.
Narrative review
Population not stated.
Endpoints were not fully described in the current record.
A review summarizes a heterogeneous set of neurologic reports.
Study administration: Not stated in the current record.
Limitations: Review-level synthesis cannot resolve mixture standardization or study-quality limitations.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 41524350
PMID 30335070
PMID 24738258